1. Home
  2. CCCC vs SOPH Comparison

CCCC vs SOPH Comparison

Compare CCCC & SOPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo C4 Therapeutics Inc.

CCCC

C4 Therapeutics Inc.

HOLD

Current Price

$4.17

Market Cap

404.7M

Sector

Health Care

ML Signal

HOLD

Logo SOPHiA GENETICS SA

SOPH

SOPHiA GENETICS SA

HOLD

Current Price

$4.96

Market Cap

374.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCCC
SOPH
Founded
2015
2011
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
404.7M
374.1M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
CCCC
SOPH
Price
$4.17
$4.96
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
2
Target Price
$12.20
$7.50
AVG Volume (30 Days)
2.9M
84.6K
Earning Date
05-06-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
16.45
N/A
EPS
N/A
N/A
Revenue
$35,947,000.00
N/A
Revenue This Year
N/A
$23.09
Revenue Next Year
N/A
$19.57
P/E Ratio
N/A
N/A
Revenue Growth
1.02
N/A
52 Week Low
$1.36
$2.59
52 Week High
$4.60
$5.70

Technical Indicators

Market Signals
Indicator
CCCC
SOPH
Relative Strength Index (RSI) 62.85 50.38
Support Level $2.13 $4.54
Resistance Level N/A $5.29
Average True Range (ATR) 0.37 0.27
MACD 0.06 0.00
Stochastic Oscillator 70.09 67.02

Price Performance

Historical Comparison
CCCC
SOPH

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.

About SOPH SOPHiA GENETICS SA

Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.

Share on Social Networks: